Location History:
- Ingelheim am Rhein, DE (2015)
- Biberach an der Riss, DE (2014 - 2022)
Company Filing History:
3 out of 1,536 
1 out of 85 
Years Active: 2014-2022
Title: Unveiling the Innovations of Ulrike Gross in Biochemical Modulation
Introduction: Ulrike Gross, a distinguished inventor hailing from Biberach an der Riss, DE, has significantly contributed to the field of biochemical modulation with his groundbreaking patents.
Latest Patents:
1. Triazolo pyridines as modulators of gamma-secretase: Ulrike Gross's invention revolves around triazolo pyridines that act as modulators of #-secretase. These compounds have the potential to treat Aβ-related pathologies, such as Alzheimer's disease.
2. Inhibitors of beta-secretase: Further showcasing his expertise, Ulrike Gross developed spirocyclic acylguanidines as inhibitors of the β-secretase enzyme (BACE1). These inhibitors have therapeutic potential for neurodegenerative disorders and diseases characterized by cognitive decline.
Career Highlights: Ulrike Gross has made notable contributions to renowned companies like Boehringer Ingelheim International GmbH and Vitae Pharmaceuticals, Inc. His dedication and innovation have fueled advancements in biochemical research and drug development.
Collaborations: Throughout his career, Ulrike Gross has collaborated with talented individuals such as Niklas Heine and Christian Eickmeier. These partnerships have fostered a culture of innovation, leading to the development of cutting-edge solutions in the field of biomedical science.
Conclusion: Ulrike Gross stands as a beacon of ingenuity in the realm of biochemical modulation, with a track record of pioneering patents that hold immense promise for the treatment of various disorders. His relentless pursuit of innovation continues to inspire and drive advancements in the field.